Keywords: HIV/AIDS drugs, Generics, Gilead Sciences, Call for price cuts, AHF, Atripla, Stribild

Study on generic HIV drugs prompts AHF to demand Gilead cuts ARV prices

Article | 16 January 2013

Print This

A new study published in the Annals of Internal Medicine that provides a snapshot of a simplified cost/benefit analysis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in